EW
Edwards Lifesciences Corporation · Healthcare · Medical - Devices
动量输入(同类管理人):
持有人广度 -4.8% ·
股份流向 -2.9% ·
净新建仓位 -5.0%
· 公式
广泛减持:持股数量下降,持有人数量减少
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q1 2025
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 14.87M | $1.28B | n/a | −3 |
| Q2 2026 | 163 | -6 | 423.46M | $38.23B | +2 | −9 |
| Q1 2026 | 173 | +2 | 408.99M | $32.75B | +6 | −5 |
| Q4 2025 | 170 | 0 | 441.50M | $37.63B | +2 | −1 |
| Q3 2025 | 24 | -1 | 280.60M | $21.82B | +1 | −3 |
| Q2 2025 | 23 | 0 | 232.09M | $18.15B | n/a | n/a |
| Q1 2025 | 20 | -1 | 112.98M | $8.18B | n/a | −1 |
| Q4 2024 | 21 | +1 | 116.40M | $8.61B | +1 | n/a |
| Q3 2024 | 19 | +1 | 77.58M | $5.12B | +2 | −1 |
| Q2 2024 | 18 | n/a | 60.09M | $5.55B | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 29.13M | -12.3% | $2.11B | 0.4% | ▼ Trim | 4 | SEC ↗ ×9 |
| 2 | State Street Global Advisors ✦ (被动) | 25.78M | -0.1% | $1.87B | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 13.38M | +42.1% | $969.90M | 1.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Geode Capital Management ✦ (被动) | 12.68M | -7.1% | $915.38M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 5 | Fisher Asset Management ✦ | 10.10M | +3.3% | $732.08M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 6 | Norges Bank ✦ (被动) | 6.49M | -21.3% | $470.54M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 7 | Millennium Management ✦ | 3.44M | +1409.8% | $249.68M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 8 | Marshall Wace ✦ | 3.03M | -47.9% | $219.66M | 0.3% | ▼ Trim | 4 | SEC ↗ ×3 |
| 9 | PRIMECAP Management ✦ | 2.30M | +12.5% | $166.68M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 1.47M | +149.7% | $106.45M | 0.3% | ▲ Add | 2 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 1.01M | +54.3% | $72.96M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 918.54K | +339.7% | $65.38M | 0.1% | ▲ Add | 4 | SEC ↗ ×6 |
| 13 | D. E. Shaw & Co. ✦ | 874.41K | -10.5% | $63.38M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 14 | T. Rowe Price ✦ | 859.69K | -73.9% | $62.31M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 15 | Baillie Gifford ✦ | 581.44K | -17.7% | $42.14M | 0.0% | ▼ Trim | 4 | SEC ↗ ×4 |
| 16 | Adage Capital Partners ✦ | 453.27K | -63.0% | $32.85M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 266.06K | +478.5% | $19.28M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 97.10K | -22.3% | $7.04M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 62.52K | -42.3% | $4.53M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 43.66K | +165.8% | $3.16M | 0.0% | ▲ Add | 4 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例,即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Soros Fund Management | $18.51M | 曾为 0.5% |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 4 持有人, 229.24K 股份, $319,498 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券:基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer · 619 股 · $53,017
Officer · 619 股 · $54,169
Officer · 544 股 · $49,534
Officer · 2.64K 股 · $237,907
Officer · 1.24K 股 · $113,417
Officer · 1.15K 股 · $105,893
Officer · 30.65K 股 · $2.79M
Officer · 619 股 · $56,967
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论